Published in Lancet on August 12, 1972
Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol (1977) 3.13
Liver-specific antigens of different species. II. Localization of a membrane antigen at cell surface of isolated hepatocytes. Clin Exp Immunol (1974) 2.36
Histocompatibility antigens, autoantibodies, and immunoglobulins in alcoholic liver disease. Br Med J (1976) 1.91
Immunological studies in patients with chronic active hepatitis. Cytotoxic activity of lymphocytes to autochthonous liver cells grown in tissue culture. Clin Exp Immunol (1975) 1.70
LM-Ag and LSP--two different target antigens involved in the immunopathogenesis of chronic active hepatitis? Clin Exp Immunol (1979) 1.59
Liver-cell-membrane autoantibody specific for inflammatory liver diseases. Br Med J (1977) 1.48
Cellular and humoral immunity to hepatitis-B surface antigen in active chronic hepatitis. Br Med J (1975) 1.47
Liver cell surface localization of hepatitis B antigen and of immunoglobulins in acute and chronic hepatitis and in liver cirrhosis. Clin Exp Immunol (1976) 1.35
Cell-mediated immune response in primary biliary cirrhosis to a protein fraction from human bile. Br Med J (1973) 1.30
Lymphocyte transformation test with liver-specific protein and phytohaemagglutinin in patients with liver disease. Clin Exp Immunol (1976) 1.28
Cell-mediated immunity to human Tamm-Horsfall glycoprotein in autoimmune liver disease with renal tubular acidosis. Br Med J (1974) 1.23
Alterations of T-cell subsets in primary biliary cirrhosis. Clin Exp Immunol (1982) 1.16
Lymphocyte cytotoxicity in chronic active hepatitis: effect of therapy and correlations with clinical and histological changes. Gut (1978) 1.11
Histological and immunological investigation of liver-specific protein (LSP) immunized rabbits compared with patients with liver disease. Clin Exp Immunol (1981) 1.10
T-lymphocyte subsets in liver tissues of patients with primary biliary cirrhosis (PBC), patients with primary sclerosing cholangitis (PSC), and normal controls. J Clin Immunol (1984) 1.10
Immune responses to the hepatitis B surface antigen and liver-specific lipoprotein in acute type B hepatitis. Gut (1977) 1.08
In vitro cell-mediated cytotoxicity in primary biliary cirrhosis and chronic hepatitis. Dysfunction of spontaneous cell-mediated cytotoxicity in primary biliary cirrhosis. J Clin Invest (1977) 1.06
T and B lymphocytes in patients with chronic active hepatitis (CAH). Clin Exp Immunol (1977) 1.03
Antibodies to a human liver membrane lipoprotein (LSP) in primary biliary cirrhosis. Gut (1980) 1.03
Disordered immunoregulatory functions in patients with chronic active hepatitis. Clin Exp Immunol (1982) 1.00
The role of immunological mechanisms in acute and chronic hepatitis. Postgrad Med J (1974) 1.00
Study of cellular immunity in experimental autoimmune hepatitis in mice. Clin Exp Immunol (1984) 0.97
Cell-mediated immunity to liver antigen in toxic liver injury. I. Occurrence and specificity. Clin Exp Immunol (1980) 0.95
Immunological aspects of chronic active hepatitis. Clin Exp Immunol (1987) 0.94
Lymphocyte transformation test with rabbit liver specific lipoprotein (RLSP) in chronic active hepatitis. Clin Exp Immunol (1979) 0.94
Cell-mediated immunity to liver antigen in toxic liver injury. II. Role in pathogenesis of liver damage. Clin Exp Immunol (1980) 0.91
Hepatocyte damage induced by lymphocytes from patients with chronic liver diseases, as detected by LDH release. Clin Exp Immunol (1978) 0.90
Antibodies against human liver-specific protein (LSP) in acute and chronic viral hepatitis types A, B and non-A, non-B. Clin Exp Immunol (1981) 0.90
Immunoglobulin deposition in liver of patients with active chronic hepatitis and antibody against smooth muscle. Br Med J (1973) 0.90
Immunological changes in liver disease. Proc R Soc Med (1977) 0.89
Immune response to rabbit liver-specific lipoprotein in acute viral hepatitis. Clin Exp Immunol (1980) 0.89
The immunology of liver disorders. Proc R Soc Med (1974) 0.86
Study of cellular immunity in experimental autoimmune hepatitis in mice: transfer of spleen cells sensitized with liver proteins. Clin Exp Immunol (1985) 0.86
A species-non-specific liver plasma-membrane antigen and its involvement in chronic active hepatitis. Biochem J (1980) 0.85
Purification and characterization of human liver specific F antigen. Clin Exp Immunol (1976) 0.83
Changes induced by vascular antigens in the aorta of guinea-pigs: immunological and morphological studies. Br J Exp Pathol (1978) 0.83
Leucocyte migration inhibition with inner and outer membranes of mitochondria and insoluble hepatocyte surface membranes prepared from rat liver in patients with chronic hepatitis and cirrhosis. Clin Exp Immunol (1976) 0.81
Corticosteroids in liver disease: possible mechanisms of action, pharmacology, and rational use. Gut (1979) 0.79
Leucocyte migration-inhibition in systemic lupus erythematosus. Ann Rheum Dis (1974) 0.78
Rosette inhibition test in chronic liver disease. J Clin Pathol (1976) 0.77
Injurious effect on rat liver mitochondria by lymphocytes from patients with primary biliary cirrhosis. Clin Exp Immunol (1976) 0.77
The effect of prednisolone in vitro on immunoglobulin production in primary biliary cirrhosis. Clin Exp Immunol (1986) 0.77
Editorial: Active chronic hepatitis. Br Med J (1974) 0.75
The pathogenesis of hepatitis B: possible mechanisms of viral replication and tissue injury. Trans Am Clin Climatol Assoc (1980) 0.75
Immunological aspects of liver disease. Gut (1991) 0.75
Detection of antibodies to Chang liver cell in sera from patients with chronic liver diseases by 125I-labelled protein A binding assay and the effect of prednisolone and 6-mercaptopurine treatment on the level of the antibodies. Clin Exp Immunol (1984) 0.75
Leucocyte migration inhibition in liver disease. J Clin Pathol (1974) 0.75
Leukocyte migration inhibition in chorioretinitis. Infect Immun (1974) 0.75
Analysis of the antigenic composition of liver specific lipoprotein using murine monoclonal antibodies. Gut (1985) 0.75
Editorial: Immunosuppressive therapy in active chronic hepatitis. Br Med J (1973) 0.75
Chronic active hepatitis. Gut (1991) 0.75
The concept of autoimmune liver disease. Bull N Y Acad Med (1976) 0.75
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
Repetitive zinc-binding domains in the protein transcription factor IIIA from Xenopus oocytes. EMBO J (1985) 20.39
A physical map of 30,000 human genes. Science (1998) 12.43
The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med (2001) 11.48
A new system for grading recommendations in evidence based guidelines. BMJ (2001) 11.13
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 9.09
The chromosome of bacteriophage T5. I. Analysis of the single-stranded DNA fragments by agarose gel electrophoresis. J Mol Biol (1972) 7.98
Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 7.43
A comprehensive genetic map of the mouse genome. Nature (1996) 6.94
Cost analysis of early discharge after hip fracture. BMJ (1993) 6.64
Deaths from low dose paracetamol poisoning. BMJ (1998) 6.63
Isolation of the virus of herpes simplex and the demonstration of intranuclear inclusions in a case of acute encephalitis. Am J Pathol (1941) 6.38
Anti-tuberculous therapy and acute liver failure. Lancet (1995) 6.27
Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med (2000) 6.07
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05
Multi-system neurological disease is common in patients with OPA1 mutations. Brain (2010) 5.37
A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science (1991) 5.14
A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature (1988) 5.11
Acute liver failure: redefining the syndromes. Lancet (1993) 4.99
Vulnerability genes or plasticity genes? Mol Psychiatry (2009) 4.96
Effects of a decision support system on the diagnostic accuracy of users: a preliminary report. J Am Med Inform Assoc (1997) 4.61
Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57
Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet (1971) 4.49
Liver transplantation in man. I. Observations on technique and organization in five cases. Br Med J (1968) 4.38
Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet (1990) 4.27
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10
Daily variation of particulate air pollution and poor cardiac autonomic control in the elderly. Environ Health Perspect (1999) 4.07
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Health literacy and health-related knowledge among persons living with HIV/AIDS. Am J Prev Med (2000) 3.70
Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet (1974) 3.61
Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology (1988) 3.51
Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess (2007) 3.40
Structured patient education: the diabetes X-PERT Programme makes a difference. Diabet Med (2006) 3.36
Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med (1978) 3.28
Divided attention: evidence for coactivation with redundant signals. Cogn Psychol (1982) 3.28
Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med (1992) 3.24
NHLBI Family Heart Study: objectives and design. Am J Epidemiol (1996) 3.21
Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature (1974) 3.17
Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis. Lancet (1976) 3.16
Investigation and control of an outbreaks of legionnaires' disease in a district general hospital. Lancet (1981) 3.14
Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol (1977) 3.13
Improved survival after orthotopic liver grafting. Br Med J (Clin Res Ed) (1981) 3.09
Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09
Mutations that alter the ability of the Escherichia coli cyclic AMP receptor protein to activate transcription. Nucleic Acids Res (1990) 3.08
Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet (1998) 3.06
Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg (1988) 3.04
Genetic studies of the Lac repressor. XV: 4000 single amino acid substitutions and analysis of the resulting phenotypes on the basis of the protein structure. J Mol Biol (1996) 2.98
Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet (1973) 2.98
Use of partial cardiopulmonary bypass during the anhepatic phase of orthotopic liver grafting. Lancet (1979) 2.98
Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ (1991) 2.94
More donor organs for transplantation. Elective ventilation proposals. J R Coll Physicians Lond (1993) 2.91
Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med (1973) 2.88
Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J (1971) 2.86
The arthropathy of idiopathic haemochromatosis. Q J Med (1968) 2.85
Hepatitis B virus infection in medical and health care personnel. Br Med J (Clin Res Ed) (1982) 2.85
Liver transplantation after paracetamol overdose. BMJ (1991) 2.81
New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol (1997) 2.78
Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet (1989) 2.76
Liver in Felty's syndrome. Br Med J (1970) 2.75
Hepatic damage and death from overdose of paracetamol. Lancet (1973) 2.70
Extrahepatic biliary atresia versus neonatal hepatitis. Review of 137 prospectively investigated infants. Arch Dis Child (1976) 2.67
Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) (1981) 2.67
Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med (1991) 2.65
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol (2010) 2.64
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology (1988) 2.60
Treatment of hepatic encephalopathy. N Engl J Med (1997) 2.60
Liver transplantation. Curr Probl Surg (1979) 2.57
Evidence for high-energy extraterrestrial neutrinos at the IceCube detector. Science (2013) 2.56
Efficient cell surface expression of class II MHC molecules in the absence of associated invariant chain. J Exp Med (1986) 2.55
A radiation hybrid map of the rat genome containing 5,255 markers. Nat Genet (1999) 2.54
Treatment of fulminant hepatic failure by polyacrylonitrile-membrane haemodialysis. Lancet (1977) 2.53
Widespread West Nile virus activity, eastern United States, 2000. Emerg Infect Dis (2001) 2.52
Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases. Gut (1998) 2.51
Orthotopic liver transplantation: the first 60 patients. Br Med J (1977) 2.50
A habitable fluvio-lacustrine environment at Yellowknife Bay, Gale crater, Mars. Science (2013) 2.50
The systemic inflammatory response syndrome in acute liver failure. Hepatology (2000) 2.47
A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation (1997) 2.46
Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology (2000) 2.45
Attentional bias in anxiety and depression: the role of awareness. Br J Clin Psychol (1995) 2.43
Developing and deploying a patient safety program in a large health care delivery system: you can't fix what you don't know about. Jt Comm J Qual Improv (2001) 2.42
Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med (1995) 2.41
Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 2.41
1 -Antitrypsin deficiency and neonatal hepatitis. Br Med J (1972) 2.40
General practice orthopaedic outpatient referrals in North Staffordshire. Br Med J (Clin Res Ed) (1983) 2.38
Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet (1974) 2.37
Prolonged expiratory apnoea: a disorder resulting in episodes of severe arterial hypoxaemia in infants and young children. Lancet (1985) 2.36
Diffusion tensor imaging of normal and injured developing human brain - a technical review. NMR Biomed (2002) 2.36
Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations. Adv Exp Med Biol (1997) 2.35
Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology (1993) 2.32
Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure. Hum Exp Toxicol (1992) 2.31